New hope for IBS sufferers: allergy drug may beat standard treatment
NCT ID NCT05815602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether ebastine, an allergy medication, works better than mebeverine, a common IBS drug, for reducing belly pain and improving daily life. About 200 adults with non-constipated IBS will take one of the two pills for 12 weeks. The goal is to see if ebastine provides more relief from symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ St-Lucas
RECRUITINGBruges, West-Vlaanderen, 8310, Belgium
Contact Email: •••••@•••••
-
AZ St-Maarten
RECRUITINGMechelen, Antwerpen, 2800, Belgium
-
GZA
RECRUITINGAntwerp, Antwerpen, 2000, Belgium
-
UZA
RECRUITINGAntwerp, Antwerpen, 2000, Belgium
-
UZLeuven
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a postbiotic soothe irritable bowel syndrome?
- Could a new drug calm the gut and stop IBS pain?
- New enzyme blend could be the key to beating bloating
- Could your family history of celiac disease hide a wheat sensitivity?
- Hidden Gut-Brain issues common in kids with IBD, study finds
- Tailored team approach shows promise for IBS sufferers